Synaffix will provide all necessary proprietary ADC technologies, including GlycoConnect™, HydraSpace™, and select toxSYN™ linker-payloads Kyowa Kirin will leverage its innovative antibody-based therapeutics pipeline to develop a portfolio of ADCs with optimized...
Ghent, Belgium – June 10, 2021 – Confo Therapeutics today announced the establishment of its Medical Advisory Board (MAB). The MAB will provide external review and strategic advice for the company’s clinical development program including the future direction of...
The four-year agreement provides benefits for portfolio companies of Forbion and BioGeneration Ventures (BGV) Lonza to provide de-risking, development and manufacturing services for large molecule biologics The agreement will streamline the gene to IND process,...
November 24th, 2020, Utrecht, the Netherlands TargED Biopharmaceuticals, a biotech spin-off of the University Medical Center Utrecht founded by Associate prof. Coen Maas, PhD, Steven de Maat, PhD, Marc van Moorsel and Kristof Vercruysse, raised EUR 1.35 million to...
• NST becomes a multi-asset clinical development company, beyond NASH• Pre-clinical studies have demonstrated broad and marked beneficial effects of SEFA-1024 on non-HDL cholesterol, triglycerides, and HDL cholesterol and glycemic control• A third clinical development...
• Flagship chemistry journal describes the development of TMTHSI (CliCr®) as a superior click reagent • Cristal applies the CliCr® platform to the rational design of CriPec® nanomedicines, also enabling modular CriVac® vaccine product development • CliCr® can be...
